title: [Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma].
abstract: BACKGROUND
  Squamous cell carcinoma (SCC) is a common pathological type of non-small cell lung cancer, and advanced lung SCC is incurable. Chemotherapy combined with anti-angiogenesis agents can prolong the patients' survival time. The aim of the study was to analyze the efficacy and safety of recombinant human endostatin (Endostar) in treating advanced lung SCC.
  
  
  METHODS
  We retrospectively analyzed the short-term efficacy and toxicity of recombinant human endostatin combined with traditional chemotherapy regimens in treating 15 advanced lung squamous cell carcinoma patients in Department of Medical Oncology retrospectively, Cancer Hospital, Chinese Academy of Medical Sciences from November 2011 to May 2015. Treatment-related survival was also analyzed.
  
  
  RESULTS
  Among the evaluble 14 patients, the best overall response was partial response in 5 patients (35.7%), stable disease in 7 patients (50.0%), and progressive disease in 2 patients (14.3%). The objective response rate (ORR) was 35.7%, and disease control rate (DCR) was 85.7%. The median progression-free survival (PFS) was 9.3 months. The main grade 3 toxicity was neutropenia (2/15, 13.3%) and vomitting (1/15, 6.7%).
  
  
  CONCLUSIONS
  Chemotherapy combined with recombinant human endostatin enabled good objective response in advanced SCC patients and had well security.
authors.affiliation: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,  Beijing 100021, China.
authors.forename: Puyuan
authors.initials: P
authors.lastname: Xing
authors.affiliation: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,  Beijing 100021, China.
authors.forename: Xuezhi
authors.initials: X
authors.lastname: Hao
authors.affiliation: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,  Beijing 100021, China.
authors.forename: Xingsheng
authors.initials: X
authors.lastname: Hu
authors.affiliation: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,  Beijing 100021, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,  Beijing 100021, China.
authors.forename: Junling
authors.initials: J
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D043169:Endostatins / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies
chemical_list: D043169:Endostatins